A Comprehensive IVD Portfolio Across Human, Veterinary, Immunology, and AST Fields

PROTIA, a leading in vitro diagnostic (IVD) company, participated in MEDICA 2025, the world’s largest medical trade fair, held from November 17–20 in Düsseldorf, Germany.
At this event, PROTIA showcased its flagship products and newly developed diagnostic solutions to the global market.

Since its launch in 1969, MEDICA has grown into one of the most influential B2B exhibitions in the medical device industry.
With 140,000㎡ of exhibition space and over 5,300 companies from more than 70 countries, it serves as a central hub for global healthcare business and innovation.
This year, approximately 350 Korean companies participated, reaffirming the competitiveness of Korean medical technology on the global stage.

PROTIA’s Complete IVD Solutions Showcased at MEDICA

At MEDICA 2025, PROTIA unveiled a comprehensive diagnostic portfolio covering human health, veterinary health, immunology, and antibiotic susceptibility testing (AST)—all in one place.

✔ Allergy-Q 192D

• A multiplex allergy testing kit capable of analyzing 176 allergens, including drug and chemical allergens, in a single test
• Powered by PROTIA’s patented parallel line multiplex technology, offering high accuracy, cost-effectiveness, and testing efficiency

✔ ANITA Canine/Feline/Equine IgE

• A veterinary diagnostic solution designed to precisely analyze allergies in dogs, cats, and horses

✔ PROTIA ANA Profile

• An immunological panel for the diagnosis of autoimmune diseases

✔ PROTIA AST DL001

• A rapid AST kit that identifies antibiotic susceptibility for faster infection treatment

✔ IMSAFE Saliva

• A saliva-based IgA immune check solution

This year’s MEDICA demonstrated PROTIA’s strong growth across multiple diagnostic sectors—from human testing to veterinary, immunology, and AST solutions.

Strengthening PROTIA’s Global Presence

Backed by strong accuracy and testing efficiency, the PROTIA Allergy-Q series is now exported to over 75 countries through more than 85 international distributors.
Exports continue to grow steadily, particularly across Europe, the Middle East, and Africa.
By the third quarter of 2025, PROTIA had already surpassed its total annual sales from the previous year.

PROTIA’s Perspective on MEDICA 2025

“MEDICA is a key global event where leading medical technology companies gather,” a PROTIA representative shared.
“It was a valuable opportunity to directly present our technological strengths and product competitiveness to buyers from around the world.”

The company also emphasized its 2025 focus on expanding global partnerships and entering new markets,
particularly in the fields of allergy, autoimmune diseases, veterinary diagnostics, immunology, and AST.

“Through the upgrade of PROTIA AST 192 Pro and collaborative research with hospitals and research institutions,
we aim to further strengthen our technical competitiveness
and solidify the PROTIA brand’s position in the global diagnostic market.”

PROTIA’s Path Forward

MEDICA 2025 reaffirmed the trust and potential PROTIA has built in the global market.
Going forward, PROTIA will continue delivering accurate, efficient, and accessible IVD solutions
that can be applied across diverse healthcare environments worldwide.